



**Ascendant Solutions, Inc. Announces Second Quarter 2008  
Net Income, Earnings per Share and EBITDA**

Dallas (August 19, 2008) - Ascendant Solutions, Inc. (the "Company") today announced its second quarter 2008 earnings. Consolidated net income for the second quarter ended 2008 increased \$1,537,000 to \$1,671,000, compared to \$134,000 for the second quarter ended 2007, resulting in net earnings per share ("EPS") of \$0.07 compared to \$0.01. Consolidated net income for the six months ended June 30, 2008 increased \$757,000 to \$1,409,000, compared to \$652,000 for the six months ended 2007, resulting in net EPS of \$0.06 compared to \$0.03. The gain on the sale of the discontinued operations of Medicine Man Pharmacies ("MedMan"), which the Company sold to Pharmacy Operations, Inc. on April 11, 2008, was \$1,714,000.

For the second quarter of 2008, the Company reported Consolidated Earnings before Interest, Taxes, Depreciation and Amortization ("EBITDA") of \$128,000 compared to consolidated EBITDA of \$446,000 in the second quarter of 2007. EBITDA for the six months ended 2008 was \$12,000 compared to \$1,326,000 for the same period of 2007. EBITDA for all periods presented include the discontinued operations of MedMan.

EBITDA is calculated as net income before deducting interest, taxes, depreciation and amortization and does not include the gain on sale of discontinued MedMan operations. Although EBITDA is not a measure of actual cash flow because it does not consider changes in assets and liabilities that may impact cash balances, the Company believes it is a useful metric to evaluate operating performance and has therefore included such measures in the discussion of operating results below.

**Healthcare Results**

The Company's subsidiary, Dougherty's Holdings, Inc. ("DHI"), which owns and operates Dougherty's Pharmacy and the discontinued MedMan operations, reported EBITDA of \$85,000 for the second quarter of 2008, compared to \$642,000 for the second quarter of 2007. EBITDA for the six month period ending June 30, 2008, was \$546,000, compared to \$1,239,000 for the same period of 2007.

Due to an overall slower economic environment, increased competition, increased pharmaceutical drug costs and declines in third party reimbursement on prescriptions, this segment has experienced slowed sales growth, declines in gross margin and increases in its operating costs during 2008, as compared to 2007. The Company's management is in the process of re-negotiating significant contracts, analyzing payroll and administrative costs and implementing processes and procedures that are expected to improve financial performance during the remaining quarters of 2008.

EBITDA for all periods presented include the discontinued operations of MedMan, which the Company sold to Pharmacy Operations, Inc. on April 11, 2008. EBITDA for the quarter ended June 30, 2008 does not include the gain on the sale of the discontinued MedMan operations of \$1,714,000. EBITDA for the discontinued MedMan operations for the second quarter ended June 30, 2008 and 2007 was (\$143,000) and \$22,000, respectively. EBITDA for the discontinued MedMan operations for the six months ended June 30, 2008 and 2007 was \$14,000 and \$70,000, respectively. The Company is expecting to use proceeds from this sale to fund additional acquisitions.

**Real Estate Advisory Services**

The Company's second quarter 2008 EBITDA from its real estate advisory services segment was \$374,000 compared to \$315,000 in the second quarter of 2007. EBITDA for the six months ended June 30, 2008 and 2007 was \$127,000 and \$1,015,000, respectively. The primary reason for the decline over last year was due to fewer fees received from advisory transactions during the first quarter of 2008.

**Corporate and Other**

The Company's results were impacted by non-cash adjustments of \$58,000 and \$105,000 in the second quarters of 2008 and 2007, respectively, representing the Company's share of the equity in losses of Fairways Frisco. For the six months ending June 30, 2008 and 2007, these non-cash adjustments were \$122,000 and \$202,000, respectively. The Company is under no obligation to fund the operating losses or debts of Fairways Frisco.

**Net Income and Earnings per Share**  
(000's omitted, except share and per share amounts, unaudited)

	Three Months Ended		Six Months Ended	
	June 30,		June 30,	
	2008	2007	2008	2007
<b>Net income</b>	\$ 1,671	\$ 134	\$ 1,409	\$ 652
<b>Basic and fully diluted net income (loss) per share</b>				
Continuing operations	\$ *	\$ 0.01	\$ (0.01)	\$ 0.03
Discontinued operations	\$ 0.07	\$ *	\$ 0.07	\$ *
	\$ 0.07	\$ 0.01	\$ 0.06	\$ 0.03

\* Less than \$0.01 per share

Average common shares outstanding, basic	22,812,858	22,615,510	22,812,858	22,582,673
Average common shares outstanding, diluted	23,052,058	22,878,255	23,052,058	22,812,363

**Earnings Before Interest, Taxes, Depreciation and Amortization**  
( \$ in thousands, unaudited)

	3 months ended June 30,				6 months ended June 30,			
	2008	2007	Change		2008	2007	Change	
			\$	%			\$	%
<b>Healthcare:</b>								
Retail Pharmacies	\$194	\$803	(\$609)	-75.8%	\$781	\$1,541	(\$760)	-49.3%
DHI Corp	(109)	(161)	52	32.3%	(235)	(302)	67	22.2%
Total Healthcare	85	642	(557)	-86.8%	546	1,239	(693)	-55.9%
<b>Real Estate:</b>								
CPOC & ASDS	374	315	59	18.7%	127	1,015	(888)	-87.5%
<b>Corporate:</b>								
Ampco Partners, Ltd	72	33	39	118.2%	112	64	48	75.0%
Fairways Frisco	(58)	(105)	47	44.8%	(122)	(202)	80	39.6%
Corp Overhead	(345)	(439)	94	21.4%	(651)	(790)	139	17.6%
Total Corp	(331)	(511)	180	35.2%	(661)	(928)	267	28.8%
<b>Total Company</b>	\$128	\$446	(\$318)	-71.3%	\$12	\$1,326	(\$1,314)	-99.1%

### **About Ascendant Solutions**

Ascendant Solutions, Inc. is a diversified financial services company that has invested in or acquired, or seeks to invest in or acquire, manufacturing, distribution or service companies. The Company also conducts various real estate activities, including performing real estate advisory services for corporate clients and, through an affiliate, purchasing real estate assets as a principal. Ascendant specializes in solving complex transactions where creative and quick solutions can add value to an enterprise.

### **Use of Non-GAAP Financial Information**

The Company uses the non-GAAP financial measure of EBITDA. The Company's management reviews these non-GAAP financial measures internally to evaluate the Company's performance and manage the operations. Additionally, the Company believes that such information also provides investors a better understanding of the Company's current operating results and provides comparable measures to help investors understand the Company's future operating results.

### **"Safe Harbor" Statements under the Private Securities Litigation Reform Act of 1995**

*This release includes certain forward-looking statements. Forward-looking statements include statements regarding the Company's expectations, beliefs, intentions, plans, projections, objectives, goals, strategies, future events or performance and underlying assumptions and other statements which are other than statements of historical facts. All forward-looking statements included in this release are based on information available to the Company on the date hereof. Such statements speak only as of the date hereof. These statements involve risks and uncertainties that could cause actual results to differ materially from those described in the statements.*

*These risks and uncertainties include, but are not limited to, (a) the following general risks: our limited funds and risks of not obtaining additional funds, certain of our subsidiaries are highly leveraged, potential difficulties managing our subsidiaries, our dependence upon management and a small staff, certain subsidiaries accounting for a significant percentage of revenue, the potential for future leveraged acquisitions, and the difficulty in predicting operations; (b) the following risks to Dougherty's Holdings, Inc.: extensive regulation of the pharmacy business, the competitive nature of the retail pharmacy industry, third party payor attempts to reduce reimbursement rates, difficulty in collecting accounts receivable, dependence upon a single pharmaceutical products supplier, shortages in qualified employees, and liability risks inherent in the pharmaceutical industry; (c) the following risks to CRESA Partners of Orange County, L.P.: the size of our competitors, our concentration on the southern California real estate market, the inability to retain senior management and/or attract and retain qualified employees, (d) the following risks to our investments in real estate: our dependence on tenants for lease revenues, the risks inherent in real estate development activities, the ability of the Frisco Square Partnerships to obtain financing on acceptable terms, the general economic conditions of areas in which we focus our real estate development activities, and the illiquidity of real estate investment; and (e) the following other risks: a majority of our common stock is beneficially owned by our principal stockholders, officers and directors, relationships and transactions with related parties, our stock is not traded on NASDAQ or a national securities exchange, effect of penny stock regulations, and litigation.*

*Because such forward-looking statements are subject to risks, uncertainties and assumptions, you are cautioned not to place undue reliance on these forward-looking statements, which reflect management's view only as of the date the forward-looking statement is made. Our forward-looking statements are based on the current expectations of management, and we undertake no obligation to update publicly any forward-looking statement for any reason, even if new information becomes available or other events occur in the future. The cautionary statements made in this report should be read as being applicable to all related forward-looking statements, wherever they appear in this report.*